Assessment and comparative analysis of renal function parameters in patients with liver cirrhosis and atrial fibrillation

Background. Currently, there is insufficient scientific data on renal function in patients with comorbid course of liver cirrhosis (LC) and atrial fibrillation (AF), as well as the effect of anticoagulant treatment on kidney function in these patients. The aim of the study is assessment and comparis...

Full description

Bibliographic Details
Published in:	Gastroenterologìa
Main Authors:	A.E. Baylo, V.V. Cherniavskyi, L.S. Hvozdetska, V.V. Tishchenko, D.O. Reshotko
Format:	Article
Language:	English
Published:	Zaslavsky O.Yu. 2023-12-01
Subjects:	liver cirrhosis atrial fibrillation kidney function warfarin dabigatran
Online Access:	https://gastro.zaslavsky.com.ua/index.php/journal/article/view/569

Similar Items

ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS
by: M. Yu. Gilyarov, et al.
Published: (2016-01-01)

New possibilities in the prevention of stroke in atrial fibrillation
by: Vladimir Anatolyevich Parfenov, et al.
Published: (2012-03-01)

Nationwide survey of catheter ablation for atrial fibrillation: The Japanese catheter ablation registry of atrial fibrillation (J-CARAF)–A report on periprocedural oral anticoagulants
by: Yuji Murakawa, MD, et al.
Published: (2015-02-01)

Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
by: N. A. Novikova, et al.
Published: (2016-11-01)

EFFECT OF ANTICOAGULANT TREATMENT OF DABIGATRAN AND WARFARIN ON HEMOSTASIS IN PATIENTS WITH LIVER CIRRHOSIS AND ATRIAL FIBRILATION.
by: A.E. Baylo, et al.
Published: (2022-02-01)

Comparison of benefit between dabigatran and warfarin among patients with atrial fibrillation: A systematic review
by: Amal K Sulieman
Published: (2016-01-01)

Effectiveness and safety of dabigatran versus warfarin in “real-world” Japanese patients with atrial fibrillation: A single-center observational study
by: Miyoko Naganuma, PhD, et al.
Published: (2017-04-01)

COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE
by: L. E. Kuvshinova, et al.
Published: (2015-09-01)

ANTICOAGULANT THERAPY FOR CHRONIC KIDNEY DISEASE AND ATRIAL FIBRILLATION: THE AXIS OF ROTATION BETWEEN THE POLES OF RISK
by: Z. D. Kobalava, et al.
Published: (2018-06-01)

ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)

Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation
by: Luca Masotti, et al.
Published: (2013-12-01)

Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
by: A. A. Zarudsky, et al.
Published: (2020-03-01)

Old and new oral anticoagulants for secondary stroke prevention in atrial fibrillation
by: Tommaso Sacquegna, et al.
Published: (2015-12-01)

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT
by: E. L. Dolgova, et al.
Published: (2015-09-01)

Trends of ambulatory oral anticoagulant prescription in five major cities of China, 2012–2017
by: Zhenwei Yu, et al.
Published: (2020-03-01)

Assessment of coagulation profile in patients with liver cirrhosis and atrial fibrillation
by: Alіna Baylo, et al.
Published: (2021-03-01)

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016-11-01)

HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION
by: S. V. Moiseev
Published: (2015-12-01)

Dabigatran etexilate for nonvalvular atrial fibrillation in real practice and promises for its use to prevent stroke
by: A.V. Fonyakin
Published: (2014-06-01)

Current approaches to periprocedural anticoagulation treatment in patients undergoing atrial fibrillation ablation
by: N. Z. Gasymova, et al.
Published: (2019-05-01)

Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation
by: Seo Yeon Yoo, et al.
Published: (2022-05-01)

Treatment of atrial fibrillation in complex patients: a case report beyond the obvious
by: Giovanni Fazio
Published: (2018-10-01)

Hypercoagulability in patients with atrial fibrillation and associated obesity: a way to hemorrhage or thromboembolia?
by: Yu. V. Kovbasniuk, et al.
Published: (2017-10-01)

New anticoagulant drugs versus warfarin in atrial fibrillation: economic evaluation and cost-effectiveness analysis
by: Mauro Silingardi
Published: (2013-12-01)

Renal outcomes of rivaroxaban compared with warfarin in Asian patients with nonvalvular atrial fibrillation: A nationwide population-based cohort study
by: So-Ryoung Lee, et al.
Published: (2023-02-01)

Comparison of Clinical and Biochemical Parameters in Atrial Fibrillation Patients Using Dabigatran and Rivoraxaban and Their Relationship with Complications
by: İrfan Aydın, et al.
Published: (2020-03-01)

Comparison of warfarin, rivaroxaban, and dabigatran for effectiveness and safety in atrial fibrillation patients with different CHA2DS2-VASc scores: a retrospective cohort study
by: Yue Zhao, et al.
Published: (2024-07-01)

The fifth anniversary of clinical use of new oral anticoagulants in non-valvular atrial fibrillation
by: A. V. Fonyakin
Published: (2015-06-01)

Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease
by: I. S. Daabul, et al.
Published: (2016-11-01)

Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction
by: Z. D. Kobalava, et al.
Published: (2021-03-01)

ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION
by: Yu. B. Belousov, et al.
Published: (2016-01-01)

Safety of Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease
by: V. I. Petrov, et al.
Published: (2019-09-01)

Anticoagulant therapy in patients with atrial fibrillation and concomitant chronic kidney disease: the results of a prospective study
by: I. S. Daabul, et al.
Published: (2019-04-01)

SELECTING AN OPTIMAL LONG-TERM ANTICOAGULANT THERAPY FOR A PATIENT WITH ATRIAL FIBRILLATION AND RECURRENT MINOR HEMORRHAGE. CLINICAL FOLLOW-UP
by: E. S. Kropacheva, et al.
Published: (2017-05-01)

PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD
by: L. Y. Koroleva, et al.
Published: (2015-12-01)

PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD
by: L. Y. Koroleva, et al.
Published: (2015-09-01)

PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD
by: L. Y. Koroleva, et al.
Published: (2015-12-01)

PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: Yu. B. Belousov, et al.
Published: (2015-12-01)

Successful use of idarucizumab for the management of intracranial hemorrhage in an elderly woman receiving dabigatran for stroke prevention in atrial fibrillation: A case report
by: Manoj Mashru, et al.
Published: (2018-10-01)